FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Matthias Schwab

Research Profile

Physiology

Chemicals & Drugs

Genes & Molecular Sequences

Occupations

Pharmacogenetics

Disorders

Concepts & Ideas

Gene Frequency

Co-author Network

Publications

TOP 3
Pilar H Saladores; Werner Schroth; Hiltrud Brauch; Jana C Precht; Matthias Schwab
Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer.
Ulrich M Zanger; Matthias Schwab
Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.
Sieglinde Angelberger; Simon Bar-Meir; Karin Dilger; Roland Greinwald; Klaus R Herrlinger; Milan Lukas; Ralph Mueller; Wolfgang Petritsch; Elke Schaeffeler; Matthias Schwab; Olga Shonova; Eduard F Stange; Alexander Teml; Walter Reinisch
Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Matthias Schwab (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Pilar H Saladores; Werner Schroth; Hiltrud Brauch; Jana C Precht; Matthias Schwab
Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer.
Expert review of molecular diagnostics 2013;13(4):349-65.
2013: Ulrich M Zanger; Matthias Schwab
Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.
Pharmacology & therapeutics 2013;138(1):103-41.
2013: Sieglinde Angelberger; Simon Bar-Meir; Karin Dilger; Roland Greinwald; Klaus R Herrlinger; Milan Lukas; Ralph Mueller; Wolfgang Petritsch; Elke Schaeffeler; Matthias Schwab; Olga Shonova; Eduard F Stange; Alexander Teml; Walter Reinisch
Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels.
Inflammatory bowel diseases 2013;19(3):590-8.
2013: Maria Thomas; Thomas S Weiss; Oliver Burk; Georg Damm; Benjamin A Kandel; Kathrin Klein; Britta Klumpp; Matthias Schwab; Ulrich M Zanger
Direct transcriptional regulation of human hepatic cytochrome P450 3A4 (CYP3A4) by peroxisome proliferator-activated receptor alpha (PPARα).
Molecular pharmacology 2013;83(3):709-18.
2013: Ute Teichgräber; Matthias Schwab; Imke Atreya; Raja Atreya; Markus F Neurath
Infliximab treatment induces levels of the active azathioprine metabolite TGTP in Crohn's disease.
Inflammatory bowel diseases 2013;19(4):E54-5.
2013: Arian Emami Riedmaier; Pascale Fisel; Anne T Nies; Elke Schaeffeler; Matthias Schwab
Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects.
Trends in pharmacological sciences 2013;34(2):126-35.
2013: Hiltrud Brauch; Matthew P Goetz; James N Ingle; Thomas E Mürdter; Werner Schroth; Matthias Schwab; Stefan Winter; Michel Eichelbaum
Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(2):176-80.
2013: Urs A Meyer; Ulrich M Zanger; Matthias Schwab
Omics and drug response.
Annual review of pharmacology and toxicology 2013;53():475-502.
2012: Anne T Nies; Elke Schaeffeler; Katja Damme; Matthias Schwab
Multidrug and toxin extrusion proteins as transporters of antimicrobial drugs.
Expert opinion on drug metabolism & toxicology 2012;8(12):1565-77.
2012: Matthias Schwab; Klaus Moerike
Antiarrhythmic drug treatment after cardioversion of atrial fibrillation.
Lancet 2012;380(9852):1467; author reply 1468.
2012: Oliver Burk; J T Fait; L Ghebreghiorghis; J P Gil; A K Nussler; R Piedade; Björn Windshügel; Matthias Schwab
Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms.
British journal of pharmacology 2012;167(3):666-81.
2012: Gökce Orhan; Matthias Schwab; Thomas V Wuttke; Anne T Nies; Holger Lerche
Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data.
Expert opinion on pharmacotherapy 2012;13(12):1807-16.
2012: E K Tarkiainen; Matthias Schwab; Janne T Backman; Mikko Neuvonen; Pertti J Neuvonen; Mikko Niemi
Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans.
Clinical pharmacology and therapeutics 2012;92(1):68-71.
2012: Arian Emami Riedmaier; Anne T Nies; Elke Schaeffeler; Matthias Schwab
Organic anion transporters and their implications in pharmacotherapy.
Pharmacological reviews 2012;64(3):421-49.
2012: Kathrin Klein; Mikko Niemi; Andreas K Nussler; Matthias Schwab; Maria Thomas; Stefan Winter; Ulrich M Zanger
PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo.
Clinical pharmacology and therapeutics 2012;91(6):1044-52.
2012: Jana C Precht; Matthias Schwab; Hiltrud Brauch; Boian Ganchev; Georg Heinkele; Thomas E Mürdter
Simultaneous quantitative analysis of letrozole, its carbinol metabolite, and carbinol glucuronide in human plasma by LC-MS/MS.
Analytical and bioanalytical chemistry 2012;403(1):301-8.
2012: Rudolf Arlanov; Rachel Brough; Darja Karpova; Reinhold Kerb; Andrew Porter; Matthias Schwab; Dennis Strand; Leszek Wojnowski; Thomas Lang
Functional characterization of protein variants of the human multidrug transporter ABCC2 by a novel targeted expression system in fibrosarcoma cells.
Human mutation 2012;33(4):750-62.
2012: Thomas E Mürdter; Elke Schaeffeler; Werner Schroth; Gabriele M Böhmer; Hiltrud Brauch; Boian Ganchev; Svitlana Igel; Reinhold Kerb; Miia Turpeinen; Ulrich Zanger; Matthias Schwab
Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites.
Human molecular genetics 2012;21(5):1145-54.
2012: E Hoffart; A K Nussler; Matthias Schwab; Wolfgang E Thasler; T S Weiss; L Ghebreghiorghis; Oliver Burk
Effects of atorvastatin metabolites on induction of drug-metabolizing enzymes and membrane transporters through human pregnane X receptor.
British journal of pharmacology 2012;165(5):1595-608.
2012: Ute Hofmann; Simon Jaeger; Cornelia Lichtenberger; Walter Reinisch; Elke Schaeffeler; Sieglinde Angelberger; Georg Heinkele; Matthias Schwab
Simultaneous quantification of eleven thiopurine nucleotides by liquid chromatography-tandem mass spectrometry.
Analytical chemistry 2012;84(3):1294-301.
2012: Timo Weiland; Thomas S Weiss; Albrecht Wendel; Martina Zimmermann; Heike Bantel; Alexander Berger; Michael Bitzer; Kathrin Klein; Alfred Königsrainer; Martin Schenk; Matthias Schwab; Tobias Speicher; Sascha Venturelli; Ulrich M Lauer
Selective protection of human liver tissue in TNF-targeting of cancers of the liver by transient depletion of adenosine triphosphate.
PloS one 2012;7(12):e52496.
2011: Katja Damme; Anne T Nies; Elke Schaeffeler; Matthias Schwab
Mammalian MATE (SLC47A) transport proteins: impact on efflux of endogenous substrates and xenobiotics.
Drug metabolism reviews 2011;43(4):499-523.
2011: Thomas Lang; Beate Pesch; Sylvia Rabstein; Matthias Schwab; Anne Spickenheuer; Stefan Winter; Thomas Brüning; Ute Hamann; Volker Harth; Christina Justenhoven; Yon-Dschun Ko; Christian Baisch; Hiltrud Brauch
The earwax-associated SNP c.538G>A (G180R) in ABCC11 is not associated with breast cancer risk in Europeans.
Breast cancer research and treatment 2011;129(3):993-9.
2011: Matthias Schwab; Elke Schaeffeler
Warfarin pharmacogenetics meets clinical use.
Blood 2011;118(11):2938-9.
2011: Boian Ganchev; Georg Heinkele; Reinhold Kerb; Matthias Schwab; Thomas E Mürdter
Quantification of clomiphene metabolite isomers in human plasma by rapid-resolution liquid chromatography-electrospray ionization-tandem mass spectrometry.
Analytical and bioanalytical chemistry 2011;400(10):3429-41.
2011: Thomas E Mürdter; Werner Schroth; Matthias Schwab; W Simon; S Winter; Michel Eichelbaum; P A Fasching; T Fehm; Georg Heinkele; L Bacchus-Gerybadze; Hiltrud Brauch
Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma.
Clinical pharmacology and therapeutics 2011;89(5):708-17.
2011: Matthias Schwab; E Schaeffeler; U M Zanger; Hiltrud Brauch; Heyo K Kroemer
[Pharmacogenomics: hype or hope?].
Deutsche medizinische Wochenschrift (1946) 2011;136(10):461-7.
2011: Lusine Danielyan; Richard Schäfer; Andreas von Ameln-Mayerhofer; Felix Bernhard; Stephan Verleysdonk; Marine Buadze; Ali Lourhmati; Tim Klopfer; Felix Schaumann; Barbara Schmid; Christoph Koehle; Barbara Proksch; Robert Weissert; Holger M Reichardt; Jens van den Brandt; Gayane H Buniatian; Matthias Schwab; Christoph H Gleiter; William H Frey
Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease.
Rejuvenation research 2011;14(1):3-16.
2011: Elke Schaeffeler; Heiko van der Kuip; Stefan Winter; Ulrich M Zanger; Claus Hellerbrand; Ute Hofmann; Hermann Koepsell; Stephan Kruck; Anne T Nies; Matthias Schwab
DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma.
Genome medicine 2011;3(12):82.
2011: Michael A Dengler; Malgorzata Doszczak; Matthias Gutekunst; Ute Hofmann; Peter Scheurich; Matthias Schwab; Annette M Staiger; Walter E Aulitzky; Heiko van der Kuip
Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis.
PloS one 2011;6(9):e25139.
2011: Stephan Riedmaier; Matthias Schwab; Stefan Winter; Ute Hofmann; Kathrin Klein; Ulrich M Zanger
Paraoxonase (PON1 and PON3) Polymorphisms: Impact on Liver Expression and Atorvastatin-Lactone Hydrolysis.
Frontiers in pharmacology 2011;2():41.
2011: Anne T Nies; Claudia Resch; Maria Rius; Elke Schaeffeler; Ute Hofmann; Matthias Schwab
Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs).
PloS one 2011;6(7):e22163.
2011: Anne T Nies; Hermann Koepsell; Katja Damme; Matthias Schwab
Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy.
Handbook of experimental pharmacology 2011;(201):105-67.
2011: Christina Justenhoven; Elke Schaeffeler; Stefan Winter; Christian Baisch; Ute Hamann; Volker Harth; Sylvia Rabstein; Anne Spickenheuer; Beate Pesch; Thomas Brüning; Yon-Dschun Ko; Matthias Schwab; Hiltrud Brauch
Polymorphisms of the nuclear receptor pregnane X receptor and organic anion transporter polypeptides 1A2, 1B1, 1B3, and 2B1 are not associated with breast cancer risk.
Breast cancer research and treatment 2011;125(2):563-9.
2010: Anne T Nies; Matthias Schwab
Organic cation transporter pharmacogenomics and drug-drug interaction.
Expert review of clinical pharmacology 2010;3(6):707-11.
2010: O Burk; S S Brenner; U Hofmann; H Tegude; S Igel; Matthias Schwab; Michel Eichelbaum; M D Alscher
The impact of thyroid disease on the regulation, expression, and function of ABCB1 (MDR1/P glycoprotein) and consequences for the disposition of digoxin.
Clinical pharmacology and therapeutics 2010;88(5):685-94.
2010: Heike Horn; Christiane Pott; Jörg Kalla; Martin Dreyling; Andreas Rosenwald; German Ott; Matthias Schwab; Elke Schaeffeler
A multiplex MALDI-TOF MS approach facilitates genotyping of DNA from formalin-fixed paraffin-embedded tumour specimens.
Pharmacogenetics and genomics 2010;20(10):598-604.
2010: Peer de Graaf; Nanne K H De Boer; D R Wong; S Karner; Bindia Jharap; Piet M Hooymans; A I Veldkamp; C J J Mulder; Ad van Bodegraven; Matthias Schwab
Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy.
British journal of pharmacology 2010;160(5):1083-91.
2010: Lusine Danielyan; Roman Klein; Leah R Hanson; Marine Buadze; Matthias Schwab; Christoph H Gleiter; William H Frey
Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease.
Rejuvenation research 2010;13(2-3):195-201.
2010: Susanne Karner; Shaojun Shi; Christine Fischer; Elke Schaeffeler; Markus F Neurath; Klaus R Herrlinger; Ute Hofmann; Matthias Schwab
Determination of 6-thioguanosine diphosphate and triphosphate and nucleoside diphosphate kinase activity in erythrocytes: novel targets for thiopurine therapy?
Therapeutic drug monitoring 2010;32(2):119-28.
2010: Christine S Zuern; Tobias Geisler; Natalia Lutilsky; Stefan Winter; Matthias Schwab; Meinrad Gawaz
Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy.
Thrombosis research 2010;125(2):e51-4.
2010: Kathrin Klein; Matthias Schwab; Miia Turpeinen; Stefan Winter; Ulrich M Zanger
Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver.
Frontiers in pharmacology 2010;1():129.
2010: S Riedmaier; Kathrin Klein; ute hofmann; J E Keskitalo; Pertti J Neuvonen; Matthias Schwab; M Niemi; Uli Zanger
UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo.
Clinical pharmacology and therapeutics 2010;87(1):65-73.
2010: Dirk Bassler; Henry L Halliday; Richard Plavka; Mikko Hallman; Eric S Shinwell; Pierre-Henri Jarreau; Virgilio Carnielli; John van den Anker; Matthias Schwab; Christian F Poets
The Neonatal European Study of Inhaled Steroids (NEUROSIS): an eu-funded international randomised controlled trial in preterm infants.
Neonatology 2010;97(1):52-5.
2009: Reinhold Kerb; Richard Fux; Klaus Mörike; Song Le; José Pedro Gil; Christoph H Gleiter; Matthias Schwab
Pharmacogenetics of antimalarial drugs: effect on metabolism and transport.
The Lancet infectious diseases 2009;9(12):760-74.
2009: Lusine Danielyan; Richard Schäfer; A Schulz; T Ladewig; A Lourhmati; M Buadze; A L Schmitt; Stephan Verleysdonk; D Kabisch; K Koeppen; G Siegel; Barbara Proksch; Torsten Kluba; A Eckert; Christoph Köhle; T Schöneberg; H Northoff; Matthias Schwab; Christoph H Gleiter
Survival, neuron-like differentiation and functionality of mesenchymal stem cells in neurotoxic environment: the critical role of erythropoietin.
Cell death and differentiation 2009;16(12):1599-614.
2009: Werner Schroth; Matthew P Goetz; Ute Hamann; Peter A Fasching; Marcus Schmidt; Stefan Winter; Peter Fritz; Wolfgang Simon; Vera J Suman; Matthew M Ames; Stephanie L Safgren; Mary J Kuffel; Hans Ulrich Ulmer; Julia Boländer; Reiner Strick; Matthias W Beckmann; Heinz Koelbl; Richard M Weinshilboum; James N Ingle; Michel Eichelbaum; Matthias Schwab; Hiltrud Brauch
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
JAMA : the journal of the American Medical Association 2009;302(13):1429-36.
2009: Anne T Nies; Hermann Koepsell; Stefan Winter; Oliver Burk; Kathrin Klein; Reinhold Kerb; Uli Zanger; Dietrich Keppler; Matthias Schwab; Elke Schaeffeler
Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.
Hepatology (Baltimore, Md.) 2009;50(4):1227-40.
2009: Hiltrud Brauch; Thomas E Mürdter; Michel Eichelbaum; Matthias Schwab
Pharmacogenomics of tamoxifen therapy.
Clinical chemistry 2009;55(10):1770-82.
2009: Miia Turpeinen; ute hofmann; Kathrin Klein; Thomas E Mürdter; Matthias Schwab; Uli Zanger
A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 2009;37(5):1017-24.
2009: Olga Renner; Simone Harsch; Elke Schaeffeler; Matthias Schwab; Dietmar M Klass; Wolfgang Kratzer; Eduard F Stange
Mutation screening of apical sodium-dependent bile acid transporter (SLC10A2): novel haplotype block including six newly identified variants linked to reduced expression.
Human genetics 2009;125(4):381-91.
2009: Ana M Gomes; Stefan Winter; Kathrin Klein; Miia Turpeinen; Elke Schaeffeler; Matthias Schwab; Uli Zanger
Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation.
Pharmacogenomics 2009;10(4):579-99.
2009: Olga Renner; Simone Harsch; Elke Schaeffeler; Stefan Winter; Matthias Schwab; Marcin Krawczyk; Jonas Rosendahl; Henning Wittenburg; Frank Lammert; Eduard F Stange
A variant of the SLC10A2 gene encoding the apical sodium-dependent bile acid transporter is a risk factor for gallstone disease.
PloS one 2009;4(10):e7321.
2009: Joachim Riethmüller; Janina Anthonysamy; Emilio Serra; Matthias Schwab; Gerd Döring; Erich Gulbins
Therapeutic efficacy and safety of amitriptyline in patients with cystic fibrosis.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009;24(1-2):65-72.
2009: Maureen J Koslowski; Irmgard Kübler; Mathias Chamaillard; Elke Schaeffeler; Walter Reinisch; Guoxing Wang; Julia Beisner; Alexander Teml; Laurent Peyrin-Biroulet; Stefan Winter; Klaus R Herrlinger; Paul Rutgeerts; Séverine Vermeire; Rachel Cooney; Klaus Fellermann; Derek Jewell; Charles L Bevins; Matthias Schwab; Eduard F Stange; Jan Wehkamp
Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease.
PloS one 2009;4(2):e4496.
2008: Rokavec Matjaz; Werner Schroth; Sandra M C Amaral; Peter Fritz; Lydia Antoniadou; Damjan Glavac; Wolfgang Simon; Matthias Schwab; Michel Eichelbaum; Hiltrud Brauch
A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.
Cancer research 2008;68(23):9799-808.
2008: Uli Zanger; Miia Turpeinen; Kathrin Klein; Matthias Schwab
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation.
Analytical and bioanalytical chemistry 2008;392(6):1093-108.
2008: Elke Schaeffeler; Uli Zanger; Michel Eichelbaum; Steven Asante-Poku; Jae-Gook Shin; Matthias Schwab
Highly multiplexed genotyping of thiopurine s-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in different ethnic groups.
Clinical chemistry 2008;54(10):1637-47.
2008: Tobias Geisler; Elke Schaeffeler; Jürgen Dippon; Stefan Winter; Verena Buse; Christian Bischofs; Christine Zuern; Klaus Moerike; Meinrad Gawaz; Matthias Schwab
CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.
Pharmacogenomics 2008;9(9):1251-9.
2008: Klaus Mörike; Kari T Kivistö; Elke Schaeffeler; C Jägle; S Igel; S Drescher; Richard Fux; C Marx; ute hofmann; C Engel; F Wagner; Ursula Delabar; Christoph Meisner; D Bail; J O Böhm; Christoph H Gleiter; Gerhard Ziemer; J G Rein; K D Hellberg; Michel Eichelbaum; Matthias Schwab
Propafenone for the prevention of atrial tachyarrhythmias after cardiac surgery: a randomized, double-blind placebo-controlled trial.
Clinical pharmacology and therapeutics 2008;84(1):104-10.
2008: Anne T Nies; Matthias Schwab; Dietrich Keppler
Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs.
Expert opinion on drug metabolism & toxicology 2008;4(5):545-68.
2008: Sieglinde Angelberger; Walter Reinisch; Clemens Dejaco; Wolfgang Miehsler; Thomas Waldhoer; Jan Wehkamp; Cornelia Lichtenberger; Elke Schaeffeler; Harald Vogelsang; Matthias Schwab; Alexander Teml
NOD2/CARD15 gene variants are linked to failure of antibiotic treatment in perianal fistulating Crohn's disease.
The American journal of gastroenterology 2008;103(5):1197-202.
2008: Matthias Schwab; Uli Zanger; Claudia Marx; Elke Schaeffeler; Kathrin Klein; Jürgen Dippon; Reinhold Kerb; Julia Blievernicht; Joachim Fischer; ute hofmann; Carsten Bokemeyer; Michel Eichelbaum
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(13):2131-8.
2008: Marco H Hofmann; Julia K Blievernicht; Kathrin Klein; Tanja Saussele; Elke Schaeffeler; Matthias Schwab; Uli Zanger
Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver.
The Journal of pharmacology and experimental therapeutics 2008;325(1):284-92.
2008: Matthias Schwab; Adrian Lupescu; Maria Mota; Eugen Mota; Andreas Frey; Perikles Simon; Peter R Mertens; Jurgen Floege; Friedrich Luft; Steven Asante-Poku; Elke Schaeffeler; Florian Lang
Association of SGK1 gene polymorphisms with type 2 diabetes.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2008;21(1-3):151-60.
2007: Richard Fux; K Mörike; A M T Pröhmer; Ursula Delabar; Elke Schaeffeler; Christoph H Gleiter; Matthias Schwab
Psoriasis aggravation and metoprolol treatment -- a prospective observational case study.
International journal of clinical pharmacology and therapeutics 2007;45(12):659-61.
2007: Oliver Burk; Matthias Schwab
The limited impact of CYP3A5 genotype for the pharmacokinetics of CYP3A substrates.
European journal of clinical pharmacology 2007;63(12):1097-8.
2007: Werner Schroth; Lydia Antoniadou; Peter Fritz; Matthias Schwab; Thomas Muerdter; Uli Zanger; Wolfgang Simon; Michel Eichelbaum; Hiltrud Brauch
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(33):5187-93.
2007: Mikael Oscarson; Oliver Burk; Stefan Winter; Matthias Schwab; Renzo Wolbold; Jürgen Dippon; Michel Eichelbaum; Urs A Meyer
Effects of rifampicin on global gene expression in human small intestine.
Pharmacogenetics and genomics 2007;17(11):907-18.
2007: Jan Wehkamp; Guoxing Wang; Irmgard Kübler; Sabine Nuding; Alex Gregorieff; Anke Schnabel; Robert J Kays; Klaus Fellermann; Oliver Burk; Matthias Schwab; Hans Clevers; Charles L Bevins; Eduard F Stange
The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4.
Journal of immunology (Baltimore, Md. : 1950) 2007;179(5):3109-18.
2007: Tanja Saussele; Oliver Burk; Julia Blievernicht; Kathrin Klein; Andreas K Nussler; N Nussler; Jan G Hengstler; Michel Eichelbaum; Matthias Schwab; Uli Zanger
Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole.
Clinical pharmacology and therapeutics 2007;82(3):265-74.
2007: Bernd Bokemeyer; Alexander Teml; C Roggel; P Hartmann; C Fischer; Elke Schaeffeler; Matthias Schwab
Adherence to thiopurine treatment in out-patients with Crohn's disease.
Alimentary pharmacology & therapeutics 2007;26(2):217-25.
2007: Uli Zanger; Kathrin Klein; Tanja Saussele; Julia Blievernicht; Marco H Hofmann; Matthias Schwab
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.
Pharmacogenomics 2007;8(7):743-59.
2007: Malgorzata Jaremko; Christina Justenhoven; Werner Schroth; Benny K Abraham; Peter Fritz; Caren Vollmert; Thomas Illig; Wolfgang Simon; Matthias Schwab; Hiltrud Brauch
Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer.
Pharmacogenetics and genomics 2007;17(7):529-38.
2007: Margalida Rotger; Heike Tegude; Sara Colombo; M Cavassini; Hansjakob Furrer; Laurent A Décosterd; Julia Blievernicht; Tanja Saussele; Huldrych Günthard; Matthias Schwab; Michel Eichelbaum; Amalio Telenti; Uli Zanger
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.
Clinical pharmacology and therapeutics 2007;81(4):557-66.
2007: Alexander Teml; Matthias Schwab; Daan W Hommes; Sven Almer; Milan Lukas; Thomas Feichtenschlager; Timothy Florin; Julia Seiderer; Wolfgang Petritsch; Bernd Bokemeyer; Wolfgang Kreisel; Klaus R Herrlinger; Peter Knoflach; Bruno Bonaz; Thomas Klugmann; Hans Herfarth; Nikolaus Pedarnig; Walter Reinisch
A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease.
Wiener klinische Wochenschrift 2007;119(17-18):519-26.
2007: Ulrich Klotz; Alexander Teml; Matthias Schwab
Clinical pharmacokinetics and use of infliximab.
Clinical pharmacokinetics 2007;46(8):645-60.
2007: Stefan Wilde; Alexander Jetter; Stephan Rietbrock; Dirk Kasel; Andreas Engert; Andreas Josting; Beate Klimm; Georg Hempel; Stefanie Reif; Ulrich Jaehde; Ute Merkel; Dagmar Busse; Matthias Schwab; Volker Diehl; Uwe Fuhr
Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity.
Clinical pharmacokinetics 2007;46(4):319-33.
2007: Alexander Teml; Elke Schaeffeler; Klaus R Herrlinger; Ulrich Klotz; Matthias Schwab
Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.
Clinical pharmacokinetics 2007;46(3):187-208.
2007: Julia Blievernicht; Elke Schaeffeler; Kathrin Klein; Michel Eichelbaum; Matthias Schwab; Uli Zanger
MALDI-TOF mass spectrometry for multiplex genotyping of CYP2B6 single-nucleotide polymorphisms.
Clinical chemistry 2007;53(1):24-33.
2006: Claudia Toscano; Sebastian Raimundo; Kathrin Klein; Michel Eichelbaum; Matthias Schwab; Uli Zanger
A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6.
Pharmacogenetics and genomics 2006;16(10):767-70.
2006: Claudia Toscano; Kathrin Klein; Julia Blievernicht; Elke Schaeffeler; Tanja Saussele; Sebastian Raimundo; Michel Eichelbaum; Matthias Schwab; Uli Zanger
Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.
Pharmacogenetics and genomics 2006;16(10):755-66.
2006: Hua-Wen Xin; Matthias Schwab; Ulrich Klotz
Transport studies with 5-aminosalicylate.
European journal of clinical pharmacology 2006;62(10):871-5.
2006: Klaus Fellermann; Daniel E Stange; Elke Schaeffeler; Hartmut Schmalzl; Jan Wehkamp; Charles L Bevins; Walter Reinisch; Alexander Teml; Matthias Schwab; Peter Lichter; Bernhard Radlwimmer; Eduard F Stange
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon.
American journal of human genetics 2006;79(3):439-48.
2006: Julia Beisner; Miriam B Buck; Peter Fritz; Jürgen Dippon; Matthias Schwab; Hiltrud Brauch; Gerhard Zugmaier; Klaus Pfizenmaier; Cornelius Knabbe
A novel functional polymorphism in the transforming growth factor-beta2 gene promoter and tumor progression in breast cancer.
Cancer research 2006;66(15):7554-61.
2006: Dagmar Busse; Silke Templin; Gerd Mikus; Matthias Schwab; ute hofmann; Michel Eichelbaum; Kari T Kivistö
Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study.
European journal of clinical pharmacology 2006;62(8):613-9.
2006: Andreas Frey; Angelika Lampert; Siegfried Waldegger; Nikola Jeck; Petra Waldegger; Ferruh Artunc; Guiscard Seebohm; Undine E Lang; Susan Kupka; Markus Pfister; Julia Hoppe; Christian Gerloff; Elke Schaeffeler; Matthias Schwab; Florian Lang
Influence of gain of function epithelial chloride channel ClC-Kb mutation on hearing thresholds.
Hearing research 2006;214(1-2):68-75.
2006: ute hofmann; Matthias Schwab; Gerd Treiber; Ulrich Klotz
Sensitive quantification of omeprazole and its metabolites in human plasma by liquid chromatography-mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006;831(1-2):85-90.
2006: Nanne K H De Boer; Walter Reinisch; Alexander Teml; Ad van Bodegraven; Matthias Schwab; Milan Lukas; Thomas Ochsenkühn; Wolfgang Petritsch; Peter Knoflach; Sven Almer; S W van der Merwe; Klaus R Herrlinger; Julia Seiderer; Harald Vogelsang; Chris J J Mulder
6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party.
Digestion 2006;73(1):25-31.
2005: Jan Wehkamp; Nita H Salzman; Edith Porter; Sabine Nuding; Michael Weichenthal; Robert E Petras; Bo Shen; Elke Schaeffeler; Matthias Schwab; Rose Linzmeier; Ryan W Feathers; Hiutung Chu; Heriberto Lima; Klaus Fellermann; Tomas Ganz; Eduard F Stange; Charles L Bevins
Reduced Paneth cell alpha-defensins in ileal Crohn's disease.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(50):18129-34.
2005: Matthias Schwab; Ulrich Klotz; ute hofmann; Elke Schaeffeler; Andreas Leodolter; Peter Malfertheiner; Gerhard Treiber
Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
Clinical pharmacology and therapeutics 2005;78(6):627-34.
2005: Kathrin Klein; Thomas Lang; Tanja Saussele; Eduardo Barbosa-Sicard; Wolf-Hagen Schunck; Michel Eichelbaum; Matthias Schwab; Uli Zanger
Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz.
Pharmacogenetics and genomics 2005;15(12):861-73.
2005: Alexander Teml; Matthias Schwab; Marieluise Harrer; Wolfgang Miehsler; Elke Schaeffeler; Clemens Dejaco; Martina Mantl; Barbara Schneider; Harald Vogelsang; Walter Reinisch
A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis.
Scandinavian journal of gastroenterology 2005;40(10):1205-13.
2005: Richard Fux; Klaus Mörike; Anne M T Pröhmer; Ursula Delabar; Matthias Schwab; Elke Schaeffeler; Gernot Lorenz; Christoph H Gleiter; Michel Eichelbaum; Kari T Kivistö
Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Clinical pharmacology and therapeutics 2005;78(4):378-87.
2005: Richard Fux; Matthias Schwab; Klaus-Peter Thon; Christoph H Gleiter; Peter Fritz
Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13):4754-60.
2005: Hua-Wen Xin; Christine Fischer; Matthias Schwab; Ulrich Klotz
Thiopurine S-methyltransferase as a target for drug interactions.
European journal of clinical pharmacology 2005;61(5-6):395-8.
2005: Florian Lang; Giovambattista Capasso; Matthias Schwab; Siegfried Waldegger
Renal tubular transport and the genetic basis of hypertensive disease.
Clinical and experimental nephrology 2005;9(2):91-9.
2005: Mikko Niemi; Pertti J Neuvonen; ute hofmann; Janne T Backman; Matthias Schwab; Dieter Lütjohann; Klaus Von Bergmann; Michel Eichelbaum; Kari T Kivistö
Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17.
Pharmacogenetics and genomics 2005;15(5):303-9.
2005: H Xin; Christine Fischer; Matthias Schwab; Ulrich Klotz
Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease.
Alimentary pharmacology & therapeutics 2005;21(9):1105-9.
2005: Jörg Zukunft; Thomas Lang; Tanja Richter; Karen I Hirsch-Ernst; Andreas K Nussler; Kathrin Klein; Matthias Schwab; Michel Eichelbaum; Uli Zanger
A natural CYP2B6 TATA box polymorphism (-82T--> C) leading to enhanced transcription and relocation of the transcriptional start site.
Molecular pharmacology 2005;67(5):1772-82.
2005: Tanja Richter; Matthias Schwab; Michel Eichelbaum; Uli Zanger
Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramide is irreversible and mechanism-based.
Biochemical pharmacology 2005;69(3):517-24.
2005: Ulrich Klotz; Matthias Schwab
Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
Advanced drug delivery reviews 2005;57(2):267-79.
2005: Kari T Kivistö; Mikko Niemi; Elke Schaeffeler; Kaisu Pitkälä; Reijo S Tilvis; Martin F Fromm; Matthias Schwab; Florian Lang; Michel Eichelbaum; Timo Strandberg
CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study.
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 2005;5(3):191-5.
2005: Heiko van der Kuip; Lara Wohlbold; Carsten Oetzel; Matthias Schwab; Walter Aulitzky
Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases.
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 2005;5(2):101-12.
2004: Richard Fux; Christoph Meisner; Matthias Schwab; Gernot Lorenz; Klaus Mörike; Christoph H Gleiter
[Rationale and methods of the UNAMET study (dose- and CYP2D6-genotype-dependent adverse drug reactions of metoprolol)--a contribution to quality improvement in pharmacotherapy].
Zeitschrift für ärztliche Fortbildung und Qualitätssicherung 2004;98(8):689-94.
2004: Matthias Schwab; Elke Schaeffeler; Ulrich Klotz; Gerhard Treiber
CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori.
Clinical pharmacology and therapeutics 2004;76(3):201-9.
2004: Kari T Kivistö; Jörg Zukunft; ute hofmann; Mikko Niemi; Sabine Rekersbrink; Swetlana Schneider; Gerd Luippold; Matthias Schwab; Michel Eichelbaum; Martin F Fromm
Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.
Naunyn-Schmiedeberg's archives of pharmacology 2004;370(2):124-30.
2004: Sebastian Raimundo; Claudia Toscano; Kathrin Klein; Joachim Fischer; Ernst-Ulrich Griese; Michel Eichelbaum; Matthias Schwab; Uli Zanger
A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects.
Clinical pharmacology and therapeutics 2004;76(2):128-38.
2004: Kari T Kivistö; Mikko Niemi; Elke Schaeffeler; Kaisu Pitkälä; Reijo S Tilvis; Martin F Fromm; Matthias Schwab; Michel Eichelbaum; Timo Strandberg
Lipid-lowering response to statins is affected by CYP3A5 polymorphism.
Pharmacogenetics 2004;14(8):523-5.
2004: Ulrich Klotz; Matthias Schwab; Gerhard Treiber
CYP2C19 polymorphism and proton pump inhibitors.
Basic & clinical pharmacology & toxicology 2004;95(1):2-8.
2004: Mikko Niemi; Elke Schaeffeler; Thomas Lang; Martin F Fromm; Mikko Neuvonen; Carl Kyrklund; Janne T Backman; Reinhold Kerb; Matthias Schwab; Pertti J Neuvonen; Michel Eichelbaum; Kari T Kivistö
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).
Pharmacogenetics 2004;14(7):429-40.
2004: Elke Schaeffeler; Christine Fischer; Dierk Brockmeier; Dorothee Wernet; Klaus Moerike; Michel Eichelbaum; Uli Zanger; Matthias Schwab
Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants.
Pharmacogenetics 2004;14(7):407-17.
2004: Nikola Jeck; Siegfried Waldegger; Angelika Lampert; Christoph Boehmer; Petra Waldegger; Philipp A Lang; Bernd Wissinger; Björn Friedrich; Teut Risler; Robert Moehle; Undine E Lang; Peter Zill; Brigitta Bondy; Elke Schaeffeler; Stephen Asante-Poku; Hannsjörg W Seyberth; Matthias Schwab; Florian Lang
Activating mutation of the renal epithelial chloride channel ClC-Kb predisposing to hypertension.
Hypertension 2004;43(6):1175-81.
2004: Monika Hitzl; Elke Schaeffeler; Berthold Hocher; Torsten Slowinski; Horst Halle; Michel Eichelbaum; Peter Kaufmann; Peter Fritz; Martin F Fromm; Matthias Schwab
Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1).
Pharmacogenetics 2004;14(5):309-18.
2004: Michel Eichelbaum; Martin F Fromm; Matthias Schwab
Clinical aspects of the MDR1 (ABCB1) gene polymorphism.
Therapeutic drug monitoring 2004;26(2):180-5.
2004: Tanja Richter; Thomas E Mürdter; Georg Heinkele; Juergen Pleiss; Stephan Tatzel; Matthias Schwab; Michel Eichelbaum; Uli Zanger
Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine.
The Journal of pharmacology and experimental therapeutics 2004;308(1):189-97.
2003: Elke Schaeffeler; Matthias Schwab; Michel Eichelbaum; Uli Zanger
CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR.
Human mutation 2003;22(6):476-85.
2003: Elke Kleideiter; Matthias Schwab; Ulrike Friedrich; Ewa Koscielniak; Beat W Schafer; Ulrich Klotz
Telomerase activity in cell lines of pediatric soft tissue sarcomas.
Pediatric research 2003;54(5):718-23.
2003: Renzo Wolbold; Kathrin Klein; Oliver Burk; Andreas K Nüssler; Peter Neuhaus; Michel Eichelbaum; Matthias Schwab; Uli Zanger
Sex is a major determinant of CYP3A4 expression in human liver.
Hepatology (Baltimore, Md.) 2003;38(4):978-88.
2003: Christoph H Gleiter; Reinhild Bücheler; Matthias Schwab
Letter to the editor concerning Ufer et al.: Eur J Clin Pharmacol 58:779-783 (2003).
European journal of clinical pharmacology 2003;59(5-6):491; author response 493-4.
2003: Jochen Buechler; Matthias Schwab; Gerd Mikus; Beate Fischer; Leopold Hermle; Claudia Marx; Georg Grön; Manfred Spitzer; Karl-Artur Kovar
Enantioselective quantitation of the ecstasy compound (R)- and (S)-N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma and urine.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;793(2):207-22.
2003: ute hofmann; Matthias Schwab; Sonja Seefried; Claudia Marx; Uli Zanger; Michel Eichelbaum; Thomas E Mürdter
Sensitive method for the quantification of urinary pyrimidine metabolites in healthy adults by gas chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;791(1-2):371-80.
2003: Christoph Köhle; Bernd Möhrle; Peter A Münzel; Matthias Schwab; Dorothee Wernet; Osama A Badary; Karl Walter Bock
Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians.
Biochemical pharmacology 2003;65(9):1521-7.
2003: Frank Röder; Matthias Schwab; Thomas Aleker; Klaus Mörike; Klaus-Peter Thon; Ulrich Klotz
Proximal femur fracture in older patients--rehabilitation and clinical outcome.
Age and ageing 2003;32(1):74-80.
2003: Matthias Schwab; Elke Schaeffeler; Claudia Marx; Martin F Fromm; Bernd A Kaskas; Joerg Metzler; Eduard F Stange; Hans Herfarth; Juergen Schoelmerich; Michael Gregor; Siegfried Walker; Ingolf Cascorbi; Ivar Roots; Ulrich Brinkmann; Uli Zanger; Michel Eichelbaum
Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis.
Gastroenterology 2003;124(1):26-33.
2003: Bernd A Kaskas; Edouard Louis; U Hindorf; Elke Schaeffeler; J Deflandre; Florian Graepler; K Schmiegelow; Michael Gregor; Uli Zanger; Michel Eichelbaum; Matthias Schwab
Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine.
Gut 2003;52(1):140-2.
2003: Matthias Schwab; Michel Eichelbaum; Martin F Fromm
Genetic polymorphisms of the human MDR1 drug transporter.
Annual review of pharmacology and toxicology 2003;43():285-307.
2002: S Wilde; Alexander Jetter; M Zaigier; Stephan Rietbrock; H Menzel; M Sieber; H Tesch; Georg Hempel; Dagmar Busse; Matthias Schwab; Stefanie Reif; Ulrich Jaehde; Volker Diehl; Uwe Fuhr
Population pharmacokinetics of cyclophosphamide, doxorubicin and etoposide in 30 patients with BEACOPP chemotherapy.
International journal of clinical pharmacology and therapeutics 2002;40(12):586-8.
2002: Reinhild Bücheler; Christoph Meisner; B Kalchthaler; H Mohr; H Schröder; Klaus Mörike; Peter Schwoerer; Matthias Schwab; Christoph H Gleiter
["Off-label" prescribing of drugs in the ambulatory care of children and adolescents].
Deutsche medizinische Wochenschrift (1946) 2002;127(48):2551-7.
2002: Taku Furuno; Maria-Teresa Landi; Mauro Ceroni; Neil Caporaso; Ilaria Bernucci; Giuseppe Nappi; Emilia Martignoni; Elke Schaeffeler; Michel Eichelbaum; Matthias Schwab; Uli Zanger
Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease.
Pharmacogenetics 2002;12(7):529-34.
2002: Matthias Schwab; Elke Schäffeler; Claudia Marx; Christine Fischer; Thomas Lang; Christoph Behrens; Michael Gregor; Michel Eichelbaum; Uli Zanger; Bernd A Kaskas
Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism.
Pharmacogenetics 2002;12(6):429-36.
2002: Monika Bredschneider; Kathrin Klein; Thomas E Mürdter; Claudia Marx; Michel Eichelbaum; Andreas K Nüssler; Peter Neuhaus; Uli Zanger; Matthias Schwab
Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation.
Clinical pharmacology and therapeutics 2002;71(6):479-87.
2002: Reinhild Bücheler; Matthias Schwab; Klaus Mörike; Bernhard Kalchthaler; Hartmut Mohr; Helmut Schröder; Peter Schwoerer; Christoph H Gleiter
Off label prescribing to children in primary care in Germany: retrospective cohort study.
BMJ (Clinical research ed.) 2002;324(7349):1311-2.
2002: Matthias Schwab; Carsten Oetzel; Klaus Mörike; Christine Jägle; Christoph H Gleiter; Michel Eichelbaum
Using trade names: a risk factor for accidental drug overdose.
Archives of internal medicine 2002;162(9):1065-6.
2002: Siegfried Drescher; Elke Schaeffeler; Monika Hitzl; ute hofmann; Matthias Schwab; Ulrich Brinkmann; Michel Eichelbaum; Martin F Fromm
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.
British journal of clinical pharmacology 2002;53(5):526-34.
2002: Marion Haubitz; Frank Bohnenstengel; Reinhard Brunkhorst; Matthias Schwab; ute hofmann; Dagmar Busse
Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency.
Kidney international 2002;61(4):1495-501.
2002: Karin Endrizzi; Joachim Fischer; Kathrin Klein; Matthias Schwab; Andreas K Nüssler; Peter Neuhaus; Michel Eichelbaum; Uli Zanger
Discriminative quantification of cytochrome P4502D6 and 2D7/8 pseudogene expression by TaqMan real-time reverse transcriptase polymerase chain reaction.
Analytical biochemistry 2002;300(2):121-31.
2002: Markus Lutz; Matthias Schwab; Ernst-Ulrich Griese; Claudia Marx; Bruno Müller-Oerlinghausen; Peter S Schönhöfer; Christoph Meisner; Christoph H Gleiter; Michel Eichelbaum; Klaus Mörike
Visual disorders associated with omeprazole and their relation to CYP2C19 polymorphism.
Pharmacogenetics 2002;12(1):73-5.
2001: Uli Zanger; Joachim Fischer; Sebastian Raimundo; T Stüven; Bernd Evert; Matthias Schwab; Michel Eichelbaum
Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.
Pharmacogenetics 2001;11(7):573-85.
2001: Manfred Spitzer; B Franke; H Walter; J Buechler; Arthur P Wunderlich; Matthias Schwab; Karl-Artur Kovar; Leopold Hermle; Georg Grön
Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans.
Neuropharmacology 2001;41(2):263-71.
2001: Thomas E Mürdter; Janet K Coller; Alexander Claviez; Frank Schönberger; ute hofmann; Peter Dreger; Matthias Schwab
Sensitive and rapid quantification of busulfan in small plasma volumes by liquid chromatography-electrospray mass spectrometry.
Clinical chemistry 2001;47(8):1437-42.
2001: Thomas Lang; Kathrin Klein; Joachim Fischer; Andreas K Nüssler; Peter Neuhaus; ute hofmann; Michel Eichelbaum; Matthias Schwab; Uli Zanger
Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver.
Pharmacogenetics 2001;11(5):399-415.
2001: Monika Hitzl; Siegfried Drescher; H van der Kuip; E Schäffeler; J Fischer; Matthias Schwab; Michel Eichelbaum; Martin F Fromm
The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells.
Pharmacogenetics 2001;11(4):293-8.
2001: Elke Schaeffeler; T Lang; Uli Zanger; Michel Eichelbaum; Matthias Schwab
High-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLC.
Clinical chemistry 2001;47(3):548-55.
2001: Ulrike Friedrich; Matthias Schwab; Ernst-Ulrich Griese; Peter Fritz; Ulrich Klotz
Telomeres in neonates: new insights in fetal hematopoiesis.
Pediatric research 2001;49(2):252-6.
2001: Matthias Schwab; Ulrich Klotz
Pharmacokinetic considerations in the treatment of inflammatory bowel disease.
Clinical pharmacokinetics 2001;40(10):723-51.
2000: Ulrike Friedrich; Ernst-Ulrich Griese; Matthias Schwab; Peter Fritz; Klaus-Peter Thon; Ulrich Klotz
Telomere length in different tissues of elderly patients.
Mechanisms of ageing and development 2000;119(3):89-99.
2000: Sebastian Raimundo; Joachim Fischer; Michel Eichelbaum; Ernst-Ulrich Griese; Matthias Schwab; Uli Zanger
Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6.
Pharmacogenetics 2000;10(7):577-81.
2000: K Kreth; Karl-Artur Kovar; Matthias Schwab; Uli Zanger
Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs.
Biochemical pharmacology 2000;59(12):1563-71.
2000: Matthias Schwab; Frank Röder; T Aleker; Susanne Ammon; Klaus-Peter Thon; Michel Eichelbaum; Ulrich Klotz
Psychotropic drug use, falls and hip fracture in the elderly.
Aging (Milan, Italy) 2000;12(3):234-9.
1999: Matthias Schwab; Frank Röder; Klaus Mörike; Klaus-Peter Thon; Ulrich Klotz
Drug-induced hyponatraemia in elderly patients.
British journal of clinical pharmacology 1999;48(1):105-6.